# Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes

Study · id `cardio:ct-nct07452913` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07452913](<https://clinicaltrials.gov/study/NCT07452913>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07452913

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 110 participants.

## Technical summary

Registry record NCT07452913. Randomized; no masking; primary purpose treatment. Start 2026-01-01 (actual); primary completion 2026-03-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 110 participants (planned count; ClinicalTrials.gov record NCT07452913, source copy `cardio:ctgov-nct07452913-2026-03-05`, retrieved 2026-10-26)
- Started: 2026-01-01 (actual) (ClinicalTrials.gov record NCT07452913, source copy `cardio:ctgov-nct07452913-2026-03-05`, retrieved 2026-10-26)
- Primary completion: 2026-03-30 (anticipated) (ClinicalTrials.gov record NCT07452913, source copy `cardio:ctgov-nct07452913-2026-03-05`, retrieved 2026-10-26)
- Completion: 2026-06-30 (anticipated) (ClinicalTrials.gov record NCT07452913, source copy `cardio:ctgov-nct07452913-2026-03-05`, retrieved 2026-10-26)
- Countries: Pakistan (ClinicalTrials.gov record NCT07452913, source copy `cardio:ctgov-nct07452913-2026-03-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ENROLLING\_BY\_INVITATION" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07452913-2026-03-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Metformin+ Empagliflozin + Sitagliptin
- Intervention (Drug): Metformin + Empagliflozin + Linagliptin
- Lead sponsor: Bahria University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Bahria University (`cardio:org-bahria-university`)

## Provenance

Content hash: e11ff5df1aba33390dab5c9a2101f83173c4a3271e935454c29ba8cc09f0e4b3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
